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Abstract: Atazanavir (ATV) is one of the latest protease inhibitors (PI) approved for the 
treatment of HIV infection. The drug has a relatively long-life (∼7 h) and large inhibitory quotient 
which allows once daily administration. It is generally well tolerated and the main side effect is 
hyperbilirubinemia, since ATV inhibits the hepatic uridin-glucoronyl-transferase. A signature 
mutation at the protease gene, I50L, may confer loss of susceptibility to the drug. Interestingly, 
it produces hypersusceptibility to all other PIs. When ATV is pharmacokinetically boosted with 
ritonavir (r) 100 mg/day, a greater genetic barrier for resistance is achieved, and generally more 
than 3 major PI resistance associated mutations are needed to result in ATV resistance. In drug-
naïve subjects, regimens based on ATV/r have shown non-inferiority compared to lopinavir 
(LPV)/r (CASTLE study) or fosamprenavir/r (ALERT trial), generally with improved tolerance 
(less diarrhea and dyslipidemia). Given its good tolerance and convenience, ATV has been 
proven to be successful as a simpliﬁ  cation strategy in switch studies (ie, SWAN and SLOAT) 
conducted in patients with complete virological suppression under other PI-based regimens. 
Finally, ATV/r-based combinations have shown to be equivalent in terms of viral response to 
other PI/r-containing regimens, including LPV/r, in rescue interventions in patients failing other 
PI regimens (ie, studies AI424-045 and NADIS).
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Introduction
The introduction of triple combination therapy following the availability of protease 
inhibitors (PIs) dramatically changed the natural history of HIV infection in the late 
1990s. When the ﬁ  rst PI (saquinavir) was marketed in 1995, the recognition of signiﬁ  cant 
gains in CD4 counts and dramatic reductions in the incidence of opportunistic events 
accompanying by unprecedent declines in virus replication produced a huge enthusiasm 
in both patients and clinicians. However, this initial joy was soon tempered when patients 
began to complain of difﬁ  culties in pursuing treatment schedules and especially when 
side effects became clearly manifest. Even worse was the recognition that disturbances 
in the metabolism of lipids and glucose and disﬁ  guring morphological features due to fat 
tissue redistribution were a new stigmatizing feature following prolonged PI exposure.
A new generation of PI compounds free of the main limitations of the ﬁ  rst-generation 
PIs has recently entered the HIV armamentarium. ATV, marketed as Reyataz® (Bristol-
Myers Squibb), may have an advantage over other PIs because of its favorable effect 
on lipid proﬁ  les, once-daily dosing, low capsule burden and a relatively favorable 
resistance proﬁ  le.1 This article reviews the main pharmacologic and clinical features 
of ATV and updates its role in the treatment of HIV infection.
Mechanism of action
ATV is an azapeptide inhibitor of the HIV-1 protease. The chemical name for ATV sulfate 
is (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-
6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentazatetradecanedioic acid dimethyl 
ester sulfate (1:1) (Figure 1). The compound inhibits the virus-speciﬁ  c processing of 
viral Gag and Gag-Pol poliproteins of HIV-1 group M subtype A, B, C, D, AE, AG, Therapeutics and Clinical Risk Management 2009:5 100
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F, G, and J in infected cells, thus preventing formation of 
mature virions.1 As measure of potency, the concentration 
that inhibits 50% of viral replication (IC50) in the absence of 
human serum ranged from 0.58 ng/mL to 5.7 ng/mL in a panel 
of susceptible viruses isolated from 31 PI-naïve HIV-infected 
patients.2,3 The presence of 40% human serum in cell cultures 
increased ATV IC50 by 2.7- to 3.6-fold, as noticed for other 
PIs. The adjusted IC50 for protein binding was estimated to 
range from 8 to 20 ng/mL against reference viral strains with 
a conventional cycle cell infection and the PhenoSenseTM 
single assay (ViroLogic Inc., South San Francisco, CA, 
USA), respectively.2
Drug resistance
Resistance patterns to ATV differ according to the population 
exposed to the drug being PI-naïve or -experienced, and to 
ritonavir (r) boosting. The presence of a single major muta-
tion in the protease gene may result in loss of susceptibility to 
ATV, but in clinical practice ATV resistance generally occurs 
when several mutations in the protease gene are present. In 
PI-naïve patients, the most frequent mutation at failure under 
ATV is I50L,4,5 while in PI-experienced patients mutations 
I84V and N88S are more commonly selected. Of note, I50L 
is only selected under ATV pressure and it causes higher 
susceptibility to other PIs such as amprenavir, darunavir, 
indinavir, lopinavir (LPV), nelﬁ  navir (NFV) and saquinavir 
(SQV).6 The prevalence of I50L in large HIV drug resistance 
mutation databases is generally very low.7
ATV is almost always prescribed boosted with r, but the 
Food and Drug Administration (FDA) allows also its use 
unboosted in selected PI-naïve patients and in simpliﬁ  cation 
strategies. In contrast, the EMEA has not approved yet the 
use of ATV without r boosting. When PIs are used without 
r boosting, drug exposures are signiﬁ  cantly lower. In this 
situation, the resistance barrier may be conﬁ  ned to a single 
key mutation (eg, I50L).
Interpretation of drug resistance mutations is complicated. 
First, a qualitative approach is usually performed identify-
ing changes that could affect drug susceptibility. As not 
all changes in the protease gene have the same inﬂ  uence 
on drug susceptibility, a quantitative score giving different 
weight to each mutation and each drug must be used. The 
International AIDS Society-USA (IAS-USA) Panel describes 
a list of mutations in the protease gene that are associated 
with resistance to ATV. This list include changes at positions 
10, 16, 20, 24, 32, 33, 34, 36, 46, 48, 50, 53, 54, 60, 62, 64, 
71, 73, 82, 84, 85, 88, 90 and 93, although the only changes 
considered as major mutations are I50L, I84V and N88S.8 
Table 1 records different algorithms developed to assist in 
the interpretation of resistance to ATV.
The accumulation of multiple PI resistance mutations has 
been shown to be a major indicator of ATV loss of susceptibility. 
In vitro analysis of the genotypic proﬁ  les of 943 PI-susceptible 
and PI-resistant clinical isolates identiﬁ  ed a strong correlation 
between the presence of several amino acid changes at speciﬁ  c 
residues (10I/V/F, 20R/M/I, 24I, 33I/F/V, 36I/L/V, 46I/L, 48V, 
54V/L, 63P, 71V/T/I, 73C/S/T/A, 82A/F/S/T, 84V, and 90M) 
and decreased susceptibility to ATV.2 In addition, data from 
PI-experienced patients revealed that the median number of 
PI-associated resistance mutations was lower in patients show-
ing virological response than in non-responders.9
As with other PIs, failure of ATV is often rather better 
explained by lack of potency than by the acquisition of 
primary resistance mutations, especially in patients without 
previous PI failure.10 In PI-experienced patients, the 
genotypic inhibitory quotient (GIQ) has been proven to be a 
good predictor of virological response to ATV, as it integrates 
both resistance mutations and drug plasma exposure.9
Cross-resistance
Although there is no obvious overlapping resistance pattern 
of ATV with any other particular PI, cross-resistance with 
ATV is observed in isolates resistant to 4 or more PIs.2 The 
NADIS French study proved that ATV/r-based rescue therapy 
is generally efﬁ  cient in most PI-experienced patients, except 
in those who had failed an LPV/r-containing regimen.11 By 
contrast, mutation L76V, selected under virologic failure with 
other PIs, produces hypersusceptibility to ATV.12
Resistance to atazanavir in HIV-1 
non B subtypes and in HIV-2
HIV variants other than subtype B show a high genetic vari-
ability within the protease, presenting many polymorphisms 
at positions associated with PI resistance in subtype B. 
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Figure 1 Chemical structure of atazanavir sulfate.Therapeutics and Clinical Risk Management 2009:5 101
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Nevertheless, primary resistance mutations do not appear 
as natural polymorphisms to ATV either in HIV-1 non-B 
subtypes or in HIV-2 isolates. Indeed, 48-week data from 
the CASTLE study have conﬁ  rmed that virologic response 
to ATV is independent from HIV subtype.13
Pharmacokinetics
ATV is rapidly absorbed with a peak plasma concentration 
(Cmax) occurring at approximately 2.5 hours and demonstrates 
non-linear pharmacokinetics. The extent of absorption is 
highly dependent on gastric pH and increases when taken 
together with a light meal. ATV is 86% bound to human serum 
proteins to both alpha-1-acid glycoprotein and albumin to a 
similar extent. ATV is a substrate for P-glycoprotein (P-gp), 
an efﬂ  ux transporter that will act to limit tissue compartment 
distribution. Like other PIs, ATV is extensively metabolized 
by hepatic cytochrome P450, primarily the CYP3A4/CYP3A5 
isoenzymes. ATV and its metabolites then undergo biliary 
and urinary excretion for 79% and 13% of an administered 
dose, respectively. Unchanged drug accounts approximately 
for 20% and 7% of the administered dose in feces and urine, 
respectively. Steady-state is achieved between days 4 and 8, 
with an accumulation of approximately 2.3-fold. Finally, ATV 
scarcely enters the cerebrospinal ﬂ  uid (CSF) and semen, with 
a CSF/plasma ratio ranging between 0.0021 and 0.0226 and a 
seminal ﬂ  uid/plasma ratio ranging from 0.11 to 4.42.1
A strategy to enhance PI pharmacokinetic parameters 
consists of the co-administration of low doses of r (boosting). 
As r is a potent inhibitor of CYP3A and to a less extent of P-gp, 
co-administration of ATV and low doses of r (100 mg/day) 
result in a decrease in ATV gastrointestinal clearance 
and ﬁ  rst-pass hepatic effect. Consequently, ATV normal 
half-life (∼7 h) is increased resulting in higher minimum 
concentration (Cmin), Cmax and AUC.1 Table 2 depicts the 
main pharmacokinetic parameters of ATV 400 and ATV/r 
300/100 mg/day.1,14
There is large inter-individual variability in ATV disposi-
tion. In a population pharmacokinetic study which included 
214 HIV patients, multiple factors that potentially could inﬂ  u-
ence the variability of ATV pharmacokinetics were assessed, 
including body weight, sex, ethnicity, creatinine clearance, 
and concomitant medications (r, nevirapine, tenofovir, aba-
cavir, lamivudine and proton pump inhibitors). Only body 
weight, r and nevirapine appeared to be highly correlated 
with ATV clearance.15
Pharmacokinetics in special populations
Pediatric
ATV has not been fully evaluated in pediatric patients and 
the optimal dosage has not been established. In the phase I/II 
Table 1 Different genotypic resistance scores for atazanavir (boosted or unboosted) in relation to clinical responses
Source Protease inhibitor Protease mutations Clinical cut-off
Colonno et al2 Atazanavir L10F/I/V, K20I/M/R, L24I, L33F/I/V, M36I/L/V, M46I/L, G48V, I54L/V, L63P,  A71I/
V/T, G73A/C/S/T,   V82A/F/T/S, I84V, L90M, or the presence of I50L alone
 versus  4
ANRS 2004
www.sante.gouv.fr
Atazanavir–ritonavir L10F/I/V, K20I/M/R, L24I, L33F/I/V, M36I/L/V, M46I/L, G48V, I54L/V, L63P,   A71I/
V/T, G73A/C/S/T,   V82A/F/T/S, I84V, L90M, or the presence of I50L alone
 versus  6
ANRS 200582 Atazanavir–ritonavir L10F/I/V, G16E, L33F/I/V, M46I/L, D60E, I84V, I85V, L90M, or the presence 
of I50L alone
 versus  3
Pellegrin et al26 Atazanavir–ritonavir L10F/I/V, K20I/M/R, L24I, M46I/L, I54L/V, Q58E, L63P, A71I/V/T, G73A/C/S/T, 
V77I,   V82A/F/T/S, I84V, L90M, or the presence of I50L alone
 versus  5
Bertoli et al83 Atazanavir L10C/I/V, V32I , E34Q, M46I/L, F53L, I54A/M/V,   V82A/F/I/T, I84V, I15E/G/L/V, 
H69K/M/N/Q/R/T/Y,  I72M/T/V
 versus  4
Bertoli et al83 Atazanavir–ritonavir G16E, V32I, K20I/M/R/T/V, L33F/I/V, F53L/Y, I64L/M/V, A71I/T/V, I85V, I93L/M  versus  3
Abbreviation:   ANRS, agence nationale de recherche sur le sida et les hépatites Virales.
Table 2 Pharmacokinetic parameters at steady state after atazanavir 
400 mg once daily and after atazanavir 300 mg with ritonavir 100 mg 
once daily with a light meal in HIV-infected patients
ATV 400 mg ATV/r 300/100 mg
Bioavailability (%) 68 Not available
Protein binding (%) 86 86
Distribution volume Not available Not available
Clh (L/h) 25.2 Not available
Clr of parent drug (%) 7 Not available
t1/2, mean ± SD (h) 6.5 ± 2.6 8.6 ± 2.3
Cmax, mean ± SD (ng/mL) 3152 ± 2231 5233 ± 3033
Tmax, median (h) 2 3
Cmin, mean ± SD (ng/mL) 273 ± 298 862 ± 838
AUC, mean ± SD (ng/mL/h) 22262 ± 20159 53761 ± 35294
Abbreviations: ATV, atazanavir; RTV, ritonavir; Clh, hepatic clearance; Clr, renal 
clearance;   T1/2, half-life; Cmax, maximum concentration;   Tmax, time at Cmax;  Cmin, minimum 
concentration;   AUC, area under the curve.Therapeutics and Clinical Risk Management 2009:5 102
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PATCG 1020A study, ATV was dosed at 310 mg/m2 body 
surface area and adjusted over 24 h in 172 children with 
a mean age of 1.2 years up to 17 years. AUC presented a 
wide range between 33,800 ng/mL/h in infants with a mean 
age of 1.2 years and 67,100 ng/mL/h in children with a 
mean age of 15 years. The Cmax values were 3900 ng/mL 
in adolescents (mean age, 17 years) and 7400 ng/mL in the 
youngest children (mean age, 1.2 years).16
Hepatic impairment
Although few data have been derived from HIV patients with 
severe hepatic dysfunction, an increased exposure to the drug in 
such individuals is anticipated. In non-HIV infected adults with 
moderate to severe hepatic impairment, AUC(0– ) was increased 
in 42% after a single 400-mg dose compared with healthy 
volunteers. On the basis on these data, a dose reduction of ATV 
is advised for patients with moderate hepatic dysfunction.1 In 
contrast, in a study conducted in 58 HCV/HIV-coinfected patients 
with compensated liver disease, ATV Cmin did not differ signiﬁ  -
cantly between patients with and without liver cirrhosis.17
Renal impairment
ATV pharmacokinetics have been evaluated in 20 adults with 
severe renal impairment, including a few on hemodialysis, 
using multiple doses of 400 mg once daily. The mean ATV 
Cmax was 9% lower, AUC was 19% higher, and Cmin was 
96% higher in subjects with severe renal impairment not 
undergoing hemodialysis, than in subjects with normal 
renal function. When ATV was administered either before 
or after hemodialysis, the geometric means for Cmax, AUC, 
and Cmin were approximately 25% to 43% lower compared 
to subjects with normal renal function. No dose adjustment 
is required in patients who are not managed with hemodialy-
sis and HIV patients with end stage renal disease managed 
with hemodialysis should receive ATV 300 with r 100 mg 
daily. ATV should not be administered to antiretroviral-
experienced patients with end stage renal disease managed 
with hemodialysis.1
Pregnancy
Although there are no adequate pharmacokinetic studies 
in pregnant women, data from other PIs suggest a 
decrease in plasma exposure during the third trimester.18 
A pharmacokinetic study was performed in 12 HIV-pregnant 
women receiving ATV/r 300/100 mg/day. The third trimester 
AUC and Cmin were approximately 40% and 21% lower, 
respectively, than in adult HIV-infected patients. All subjects 
reaching delivery achieved plasma HIV-RNA  50 copies/mL 
and all infants tested were HIV-negative and presented 
normal bilirubin values through day 14. However, 1 newborn 
developed grade 3 hyperbilirubinemia at day 15.19 In another 
study, total bilirubin concentrations were above normal limits 
at birth and day 3, and 3 newborns had transient neonatal 
jaundice which did not require phototherapy.20
Drug interactions
ATV is a substrate and inhibitor of CYP3A (Ki value of 0.84 
to 1.0 μM). ATV also inhibits CYP2C8 (Ki = 2.1 μM) and 
UGT1A1 (Ki = 1.9 μM). It is also a substrate and inhibitor of 
P-gp with levels comparable to verapamil, a well known P-gp 
inhibitor.21,22 Therefore, co-administration of ATV and drugs 
primarily metabolized by CYP3A, CYP2C8, or UGT1A1 
and/or substrates of P-gp may result in increased plasma 
concentrations of the concomitant drug, which potentially 
could enhance or prolong both their therapeutic and adverse 
effects. The magnitude of the mediated drug interaction may 
change when ATV is co-administered with r. On the other 
hand, drugs that induce CYP3A4 and/or P-gp may decrease 
ATV plasma concentrations and therefore compromise ATV 
therapeutic effect. Finally, drugs affecting the gastric pH may 
alter ATV solubility and consequently its bioavailability.1 ATV 
and ATV/r drug interactions are summarized in Table 3.
As shown in Figure 2, raltegravir, the ﬁ  rst integrase 
inhibitor approved for the treatment of HIV infection, is 
metabolized by glucuronidation, but interactions with ATV 
do not generally result in increased hyperbilirubinemia since 
different UGT isoenzymes are subject to ATV inhibition and 
raltegravir metabolism, respectively.
Therapeutic drug monitoring (TDM)
Monitoring plasma drug concentrations has proven to be 
useful for PIs, and may allow tailoring of antiretroviral 
therapy.23 ATV plasma concentrations demonstrate high 
inter-individual variability, even in the presence of r, along 
with a low intra-individual variability, supporting TDM. The 
deﬁ  nition of a therapeutic range for ATV concentrations has 
been pursued for a while in an attempt to minimize side effects, 
mainly hyperbilirubinemia while ensuring maximal efﬁ  cacy, 
especially when r unboosted ATV needs to be used.24
Atazanavir plasma concentrations 
as predictors of virological response
Several studies have evaluated the relationship between ATV 
plasma levels and virological response.9,25,26 A threshold 
of 0.15 mg/L has been proposed for antiretroviral-naïve 
patients based on results of a retrospective study performed Therapeutics and Clinical Risk Management 2009:5 103
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on 51 patients. In that study, virological responses according 
to ATV trough concentrations (Ctrough) were as follows: 58.3% 
when  0.15 mg/L, 75% when values between 0.15 and 
0.85 mg/L, and 100% when  0.85 mg/L.25
In PI-experienced patients, the combined use of 
pharmacokinetics and resistance information has been 
proposed as a better predictor of virological response than use 
of these two variables separately.27,28 The genotypic inhibitory 
quotient (GIQ), deﬁ  ned as the ratio of the minimum plasma 
drug concentration to the number of resistance mutations in the 
protease gene, has been associated with virological response 
to ATV in PI-experienced patients.9,25,26 A GIQ   0.10 mg/L 
mutation has been found to signiﬁ  cantly predict virological 
response at 24 weeks. Mutations more signiﬁ  cant to be 
included in the GIQ model are the following: L10F/I/V, 
K20M/R, L24I, D30N, V32I, L33F, M36I/L, I47V/A, G48V, 
I50V, I50L, F53L, I54V/L/A/M/T/S, L63P, A71V/T, G73S, 
V77I, V82A/F/T, I84V, N88D/S and L90M.25
Atazanavir plasma levels as predictors 
of hyperbilirubinemia
Several studies have found an association between ATV 
plasma concentrations and serum bilirubin levels.9,25,29,30 
However, at this time there are not enough data available to 
deﬁ  ne threshold for scleral jaundice, which otherwise may 
vary from one subject to another, although it can generally 
be recognized when serum bilirubin goes up 2.5 mg/dL.
In HIV-HCV-coinfected patients on stable ATV therapy 
who begin treatment with pegylated interferon plus ribavirin, 
hemolytic anemia caused by ribavirin may result in increased 
levels of bilirubin (Figure 2). In a study performed in 72 
HCV/HIV-coinfected patients treated for hepatitis C, up to 
45% of those on ATV experienced serum bilirubin increases 
greater than 1 mg/dL compared with only 3% of individuals 
under other antiretroviral regimens. Indeed, the proportion of 
patients on ATV who experienced hyperbilirubinemia grade 
3–4 increased 2.5-fold after beginning hepatitis C therapy 
(from 9% to 45%).31
Another population in which TDM for ATV may be 
particularly useful is the subset of HIV patients treated con-
comitantly with TDF, the most widely used antiretroviral 
agent. The co-administration of ATV and TDF results in 
a 20% to 40% reduction in ATV plasma concentrations.1,32 
Therefore, the current advice is to give ATV boosted with 
low doses of r when taken along with TDF. However, this 
intervention may be regarded as less convenient for drug-
naïve subjects because of the need for an additional extra 
pill of r, which has to be kept in the refrigerator and often 
produces gastrointestinal disturbances. More importantly, it 
increases the risk of jaundice and eliminates the lipid-friendly 
behavior of ATV.33 In a retrospective study performed in 
56 HIV patients with undetectable plasma HIV-RNA under 
a triple regimen containing ATV/r 300/100 mg once daily 
(qd), TDM was useful to allow a switch to ATV 400 mg qd. 
A total of 79% were taking concomitantly TDF. At week 
24, therapeutic levels (Ctrough   150 ng/mL) were kept in all 
patients but 4. TDF was part of the antiretroviral regimen in 
all 4 cases. From a total of 29 (52%) patients on ATV/RTV 
showing grade 3–4 hyperbilirubinemia, only 7 (12%) still 
suffered from it upon switching to ATV 400 mg qd. Undetect-
able viral load was maintained in all patients but one in whom 
subtherapeutic ATV concentrations were seen. Therefore, 
TDM can be a useful tool to identify the subset of ATV treated 
patients in whom removal of r could be attempted without 
risk of suboptimal plasma ATV exposure and subsequent 
virological failure.34
Pharmacogenetics
Hyperbilirubinemia is the most common adverse effect in 
patients treated with ATV. The underlying mechanism is an 
inhibition by ATV of the uridine-glucuronosyl-transferase 
(UGT) 1A1 enzyme, which is involved in bilirubin 
conjugation (Figure 2).35,36 In this context, genetic factors 
affecting ATV disposition and/or UGT1A1 function could 
alter bilirubin levels.
Several single nucleotide polymorphisms (SNP) with 
potential consequences in the expression of P-gp have been 
identiﬁ  ed in the gene that codiﬁ  es for P-gp, named multidrug 
resistance gene 1 (MDR1). In patients taking ATV 400 mg qd, 
the 3435C   T polymorphism has been associated with lower 
ATV plasma levels and lower serum bilirubin levels.29 Accord-
ingly, the risk for developing severe hyperbilirubinemia was 
as high as 24% in subjects with MDR1 wild-type alleles 
but as low as 0% in those homozygous for the 3435C   T 
polymorphism. These results have been conﬁ  rmed thereafter 
in patients on ATV/RTV, as patients with the CC genotype 
show signiﬁ  cantly higher median ATV Ctrough concentrations 
than those with CT/TT genotypes (939 versus 376 ng/mL, 
respectively).30 The C3435T polymorphism is a silent change 
and thus it is unlikely that it directly inﬂ  uences the expression 
of the MDR1 gene.37 Most likely, this polymorphism may be 
linked to one or more other unidentiﬁ  ed changes in MDR1 
or distinct metabolizing enzyme genes. The 2677G   T 
polymorphism has recently been suggested as the possible 
candidate.38 Persons homozygous for the MDR1 2677T allele, 
which is frequently linked to the 3435T allele, show enhanced Therapeutics and Clinical Risk Management 2009:5 104
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Table 3 Main drug interactions with atazanavir 400 mg or atazanavir/ritonavir 300/100 mg/day
Family Drug Effect on concentration Recommendation
Antiarrhythmics amiodarone, bepridil, 
lidocaine, quinidine
↑ antiarrhythmic Caution is warranted, TDM recommended.
Anticoagulants warfarin ↑ warfarin Monitoring of INR is recommended.
Anticonvulsants carbamazepine, lamotrigine, 
phenobarbital, phenytoin
expected ↓ ATV Use with caution.
Antidepressants tricyclic antidepressants
trazodone
↑ tricylcic antidepressants
↑ trazodone
Use with caution, TDM is recommended.
TDM is recommended and lower trazodone doses should 
be used
Antifungals itraconazole, ketoconazole ↑ itraconazole, 
ketoconazole (ATV 400)
If ATV is used with RTV, itraconazole or ketoconazole doses 
of  200 mg/day should be used with caution.
Antihistamines astemizole, terfenadine no data available ATV/r should not be used in combination with drugs that 
are substrates of the CYP3A4 and have narrow therapeutic 
windows, such as terfenadine and astemizole.
Antimicrobial agents clarithromycin ↑ clarithromycin
↓ 14-OH-clarithromycin
↑ ATV concentrations
Dose reductions by 50% should be considered. 
Combination with boosted ATV has not yet been studied.
Antineoplastics irinotecan ↑ irinotecan Contraindicated
Antimycobacterials rifabutin
rifampicin
↑ rifabutin
severe ↓ ATV
Reduce rifabutin dose to 150 mg every other 
day or 3 times/week.
Contraindicated.
Antiretroviral agents NRTIs:
didanosine
tenofovir
↓ ATV, ↓ didanosine
↓ ATV, ↑ tenofovir
Didanosine should be administered (with food) 1 h before or 
2 h after ATV/r intake.
Avoid combination of tenofovir with r unboosted ATV.
NNRTIs:
efavirenz
nevirapine
etravirine
↓ ATV
expected ↓ ATV
↑ etravirine, ↓ ATV
The recommended dose in treatment-naïve patients 
is ATV/r 300/100 mg/day. No recommendation has been 
established in treatment-experienced patients.
Co-administration is not recommended.
ATV should be boosted with r.
IPs:
indinavir
saquinavir
(soft gelatin capsules)
tipranavir
↑ saquinavir
expected ↓ ATV
Contraindicated due to synergistic effect 
on hyperbilirubinemia.
Appropiate recommendations for this combination have not 
been established. TDM is recommended.
ATV and tipranavir should not be co-administered.
INI:
raltegravir ↑ raltegravir The clinical relevance of these data is unknown. 
No changes in raltegravr dosign are recommended.
Benzodiazepines midazolam, triazolam ↑ midazolam, triazolam Contraindicated.
Calcium channel 
blockers
diltiazem
felodipine, nifedipine, 
nicardipine, verapamil
↑ diltiazem and 
desacetyl-diltiazem
↑ felodipine, nifedipine, 
nicardipine, verapamil
Caution is warranted. 50% dose reduction of diltiazem 
should be considered.
Caution is warranted and ECG monitoring is recommended. 
Dose titration should be considered.
Corticosteroids ﬂ  uticasone ↑ ﬂ  uticasone Caution is warranted.
Ergot derivatives dihydroergotamine, 
ergotamine,ergonovine, 
methylergonovine
↑ ergot derivatives Contraindicated.
GI motility agent cisapride ↑cisapride Contraindicated.
Acid suppressive 
therapy
antiacids ↓ ATV ATV should be adminsitered 2h befote or 1h alter intake of 
antiacids.
(Continued)Therapeutics and Clinical Risk Management 2009:5 105
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Bilirubin
Atazanavir
Indinavir
Raltegravir
Glucoronic
metabolism
Inhibitory
competition
1A9
1A1
1A3
Gilbert: UGT 1A1*28
UGT
Figure 2 Antiretrovirals, bilirubin and UGT inhibition.
Table 3 (Continued)
Family Drug Effect on concentration Recommendation
H2 receptor antagonists ↓ ATV H2 Receptor antagonist should not exceed a 40 mg dose 
equivalent of famotidine twice daily and ATV should be 
administered with r simultaneously, with and/or at least 
10 hours after the dose of the H2-receptor antagonist.
proton pump inhbitors ↓ ATV ATV/r is recommended. Proton-pump inhibitor dose should 
not exceed a 20 mg dose/day, equivalent of omeprazole and 
must be taken approximately 12 hours prior to ATV/RTV in 
antiretroviral-naïve patients. Proton-pump inhibitors should 
not be used in treatment-experienced patients.
Herbal products St. John’s wort expected ↓ ATV Contraindicated.
HMG-CoA reductase 
Inhbitors
lovastatin, simvastatin
atrovastatin, rosuvastatin
↑ lovastatin, simvastatin
↑atorvastatin, rosuvastatin
Contraindicated.
Use the lowest possible dose of atorvastatin or rosuvastatin 
with careful monitoring or consider other HMG-CoA 
reductase inhibitor such as pravastatin or ﬂ  uvastatin.
Immuno-suppressants cyclosporine A, sirolimus, 
tacrolimus
↑ immunosuppressants TDM is recommended.
Neuroleptics pimozide ↑ pimozide Contraindicated.
Oral contraceptives ethinyl estradiol, 
norethindrone
↓↑ oral contraceptives Due to possible alteration of oral contraceptives 
concentrations, alternative/additional contraceptive measures 
should be used when co-administered with ATV or ATV/r.
PDE5 inhibitors sildenaﬁ  l, tadalaﬁ  l, vardenaﬁ  l ↑ sildenaﬁ  l, tadalaﬁ  l, 
vardenaﬁ  l
Do not exceed 25 mg of sildenaﬁ  l in 48 h, 10 mg of taldalaﬁ  l 
in 72 hours or 2.5 mg of vardenaﬁ  l in 72 h.
Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease Inhibitor; INI, integrase Inhibitor; ATV, 
atazanavir; RTV, ritonavir; TDM, therapeutic drug monitoring; INR, international normalized ratio; ECG, electrocardiogram.Therapeutics and Clinical Risk Management 2009:5 106
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constitutive CYP3A4 expression in the liver and gut when 
compared to subjects homozygous for the 2677G allele.39
Several polymorphisms at the UGT1A1 gene have 
been described. The wild type allele (UGT1A1*1) contains 
6 TA repeats in the promoter (TA6) whereas the most 
common variant allele (UGTA1A1*28) contains 7 repeats 
(TA7) and is the main one responsible for the mild form of 
Gilbert’s syndrome, an inherited unconjugated hyperbili-
rubinemia disorder.40–42 In a retrospective study conducted 
in 118 patients on a stable ATV/r regimen, the proportion 
of patients with grade 3–4 hyperbilirubinemia varied with 
distinct UGT1A1 genotypes: 80% for 7/7, 29% for 6/7 and 
18% for 6/6. In the multivariate analysis, having at least one 
TA7 allele at UGT1A1 signiﬁ  cantly predicted grade 3–4 
hyperbilirubinemia.30
Rotger et al quantiﬁ  ed the relative contribution of the 
UGT1A1*28 allele and different antiretroviral combinations 
on the risk of hyperbilirubinemia in 96 HIV-infected patients. 
ATV bilirubin levels increased by 0.87 mg/dL, while it 
was 0.46 mg/dL using indinavir. Patients homozygous for 
UGT1A1*28 had bilirubin levels increased by 0.3 mg/dL. As 
a result, 67% of individuals homozygous for UGT1A1*28 
and receiving either ATV or indinavir had hyperbilirubinemia 
in the jaundice range ( 2.5 mg/dL), versus only 7% of those 
with the common allele not receiving any of these drugs. The 
implementation of UGT1A1*28 genotyping before initiation 
of antiretroviral therapy would lead to a theoretical 75% 
reduction in the number of patients experiencing jaundice.42
Other polymorphisms in the genes encoding for the 
UGT isoenzymes could also be associated with Gilbert’s 
syndrome.40,41 Lankisch et al examined the effects of different 
polymorphisms in UGT1A1 (UGT1A1*28), UGT1A3 (-66) 
and UGT1A7 (−57T   G, W208R, N129K and R131K) genes 
on the risk of hyperbilirubinemia in patients treated with ATV. 
These isoenzymes are all inhibited by ATV. Interestingly, 
the homozygote haplotype for all 4 variants was present in 
up to 41% of patients with grade 3/4 and in 100% of patients 
with grade 4 hyperbilirubinemia. Therefore, the combination 
in homozygosis at *28, UGT1A7-57G, UGT1A3-66C and 
UGT1A7 was identified as highly predictive of severe 
hyperbilirubinemia under ATV therapy.41
Toxicity
ATV is generally well tolerated, as shown by the fact that only 
5% to 10% of patients discontinued the drug due to adverse 
events in the main registrational studies with 48 weeks of 
follow-up. Indirect (unconjugated) bilirubin elevation is the 
most frequent side effect reported with ATV therapy and 
is due to inhibition of the UGT, as mentioned above. This 
unconjugated bilirubin elevation is frequently seen within the 
ﬁ  rst months on ATV therapy and tends to slightly decline 
thereafter due to metabolic compensation mechanisms. This 
laboratory abnormality only achieves clinical relevance 
(grade 3–4) in up to one third of patients across studies. 
Jaundice is infrequent ( 10%) and excessive bilirubin 
elevations leading to ATV discontinuation are rare (around 
1% of treated patients).1 The risk for hyperbilirubinemia 
seems to be associated to ATV plasma levels, and is more 
frequent when high doses of ATV are given (ie, 600 mg qd) 
or when ATV is boosted with r.9,25,29,30 Of note, hyperbiliru-
binemia is completely reversible after stopping ATV.
Grade 3–4 elevations in transaminases have been 
observed in 3% to 14% of patients receiving ATV. Liver 
enzyme elevations do not correlate with increased serum 
bilirubin and are more frequently seen in HIV subjects 
with underlying chronic hepatitis B or C. In the AI424-007 
study,43 in which ATV was given in combination with didano-
sine and stavudine, grade 3-4 elevations in transaminases 
occurred in 20% of patients with chronic hepatitis B and 
in 40% of patients with chronic hepatitis C, but in  10% 
of HIV-monoinfected individuals. In studies AI424-00844 
and AI424-034,5 ALT levels  5 times the upper limit of 
normality were seen respectively in 15%, 14% and 17% of 
seropositive patients for hepatitis B or C treated with ATV, 
efavirenz and nelﬁ  navir. In study AI424-045,33 20 patients 
treated with ATV/r and 18 with LPV/r, all seropositive for 
hepatitis B and/or C, experienced increases in ALT levels 
 5 times the upper limit of normality in 25% (5/20) and 6% 
(1/18) of cases, respectively. Therefore, liver function tests 
should periodically be monitored in patients on ATV with 
underlying chronic liver disease.
Patients on ATV may occasionally complain of gastro-
intestinal disturbances, although symptoms are generally 
mild. In the AI424-007 study,43 grade 3–4 nausea/vomiting, 
abdominal pain, or diarrhea occurred in only 2% to 3% of 
patients. Of note, these side effects do not seem to rise when 
ATV is boosted with r. Indeed, in the AI424-045,33 the inci-
dence of grade 2–4 gastrointestinal symptoms was 3% in the 
ATV/r arm but was much higher in the LPV/r arm (11%).
Some concern has been raised with respect to the potential 
cardiac toxicity of ATV, following sporadic reports in the 
literature. This adversity was not originally reported during 
the clinical development of the drug and has only rarely been 
noticed in the post-marketing period.45 ATV has been shown 
to prolong the PR interval in electrocardiograms performed 
on healthy volunteers as well as in HIV-infected patients.46 Therapeutics and Clinical Risk Management 2009:5 107
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Abnormalities in atrioventricular conduction are generally 
asymptomatic, concentration-dependent and limited to 
ﬁ  rst-degree atrioventricular block. Anecdotal reports of 
second-degree atrioventricular block and other conduction 
abnormalities have been published.1 A retrospective analysis 
of patients enrolled in the ATV expanded access program 
(AI424-900 study) has shown that QRS intervals increased 
by a median of 5 ms in 56 out of 75 (74.7%) antiretroviral-
experienced patients (66.7% male), using either boosted 
or unboosted ATV. The PR and the QTc intervals did not 
change signiﬁ  cantly. Interestingly, new asymptomatic bundle 
branch blocks were observed in 4 patients.47 According to 
pooled data from the manufacturer’s prescribing information, 
the incidence of QTc interval prolongation in a total of 
1793 patients treated with ATV was comparable to that 
of patients receiving other PIs, with none of the patients 
showing a QTc interval  500 ms.1 Since pre-existing cardiac 
conduction abnormalities was an exclusion criterion in many 
early ATV studies, the prevalence of electrocardiogram 
abnormalities in unselected populations remains unknown. 
An additive effect of ATV and drugs that prolong the PR 
interval (eg, beta-blockers, verapamil, digoxin) and the QT 
interval cannot be excluded; consequently, when possible 
these combinations should be avoided. Altogether, these 
observations show that periodic electrocardiogram monitor-
ing is worthwhile in patients treated with ATV, particularly 
when boosted with r.
Cases of nephrolithiasis in patients on ATV have been 
reported after marketing of ATV.48 This complication 
resembles the well known side effect of indinavir, which 
was able to produce kidney stones. In some instances, ATV 
crystals have been demonstrated in urine. However, this 
complication is very rare. In one retrospective study the 
prevalence of ATV-associated urolithiasis was 0.97%.49 
Patients with low water intake, high urinary pH, and prior 
history of urinary stones are at higher risk for ATV-associ-
ated urine crystallization.
Unlike other PIs, ATV does not seem to negatively 
impact the lipid proﬁ  le. ATV also seems to have less impact 
on insulin and overall on glucose metabolism than all other 
PIs. Following this observation a lack of involvement of the 
drug in morphological lipodystrophy abnormalities has been 
presumed, which is somewhat unique for PIs, although a 
longer follow-up is needed to conﬁ  rm this singularity.50
Clinical experience
Atazanavir in treatment-naïve subjects
ATV has been compared with other potent agents such as 
nelﬁ  navir, efavirenz, saquinavir and LPV/RTV as part of triple 
therapy with two nucleoside reverse transcriptase inhibitors 
(NRTI) in treatment-naïve patients (Table 4). Two studies, 
AI424-00743 and AI424-008,44 compared different doses 
of unboosted ATV with nelﬁ  navir along with didanosine + 
stavudine or lamivudine + stavudine, respectively. The viro-
Table 4 Main randomized studies with atazanavir in antiretroviral-naïve patients
Study Phase No Backbone Regimens Follow-up
(weeks)
% patients achieving
plasma HIV-RNA 
 400 copies/mL (ITT)
% patients achieving 
plasma HIV-RNA 
 50 copies/mL (ITT)
AI424-00743 II 420 d4T + ddI ATV 200 mg qd
ATV 400 mg qd
ATV 500 mg qd
NFV 750 mg tid
48 61
64
59
56
28
36
42
39
AI424-00844 II/III 467 d4T + 3TC ATV 400 mg qd
ATV 600 mg qd
NFV 1250 mg bid
48 64
67
53
35
36
34
AI424-0345 III 810 ZDV + 3TC ATV 400 mg qd
EFV 600 mg qd
48 70
64
32
37
CASTLE55 III 883 TDF + FTC ATV/RTV 300/100 mg qd
LPV/RTV 400/100 mg bid
48 86
82
78
76
AI424-08951 IV 200 3TC + d4T-XR ATV 400 mg qd
ATV/RTV 300/100 mg qd
96 85
86
70
75
ALERT54 IV 106 TDF + FTC ATV/RTV 300/100 mg qd 
FPV/RTV 1400/100 mg qd
48 87
79
83
75
Abbreviations: ITT, intent-to-treat;   VL, viral load; 3TC, lamivudine; d4T, stavudine; d4T-XR, extended-release stavudine; ddI, didanosine; TDF, tenofovir disoproxil fumarate;  ATV, 
atazanavir; LPV, lopinavir/ritonavir; NFV, nelﬁ  navir; FPV, fosamprenavir; RTV, ritonavir; EFV, efavirenz;  ZDV,  zidovudine; bid, twice daily; qd, once daily; tid, three times daily.Therapeutics and Clinical Risk Management 2009:5 108
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logical response to both PIs was similar in terms of mean 
viral load reduction at 48 weeks and proportion of patients 
attaining undetectable viremia. Likewise, the increase in 
CD4 + T lymphocytes was similar for all groups in both stud-
ies. ATV and nelﬁ  navir regimens were generally well toler-
ated, with the best efﬁ  cacy/safety proﬁ  le being found when 
ATV was given as 400 mg qd. Indeed, this was the selected 
dose for later studies. The metabolic indulgence of ATV 
was one of the most striking ﬁ  ndings of the AI424-007 and 
AI424-008 studies. Increases in total cholesterol at 48 weeks 
were 25% and 28% for nelﬁ  navir in each trial, but only 5% 
and 7% for ATV (400 mg qd), respectively (p   0.05). The 
same favorable behavior was seen for triglycerides (1.5% 
and 7% increase in each study) over nelﬁ  navir (42% and 
50% increase in each study).
The AI424-034 study5 compared unboosted ATV with 
efavirenz (one if not the most preferred third agent in drug-
naïve patients) in combination with zidovudine + lamivudine 
as the nucleoside backbone. Despite the recruitment of many 
patients with high viral loads (42% with  5 log HIV-RNA 
copies/mL) and low CD4 counts (median of 282 cells/μL), the 
performance was excellent and comparable after 48 weeks: 
70% and 64% of patients with ATV and efavirenz, respec-
tively, attained  400 HIV-RNA copies/mL. Some technical 
problems in the processing of specimens led to low rates of 
patients with values  50 copies/mL in both groups (32% with 
ATV and 37% with EFV). The regimens were comparable 
with respect to the magnitude and rate of CD4 + T cell gains. 
Interestingly, ATV treatment was associated with a more 
favorable lipid proﬁ  le than was efavirenz treatment. In fact, 
the mean increase in total and low-density lipoprotein (LDL) 
cholesterol was signiﬁ  cantly higher for efavirenz than for 
ATV (+21% and +18% versus +2% and +1%, respectively). 
The high-density lipoprotein (HDL) cholesterol fraction rose 
in both groups, but was more pronounced with efavirenz than 
with ATV (+24% versus +13%; p   0.001). Finally, mean 
triglyceride levels decreased with ATV (–9%) and increased 
with efavirenz (+23%) (p   0.001). No signiﬁ  cant variations 
in glucose metabolism were noticed in either group, although 
patients on efavirenz tended to show slight increases in 
fasting insulin concentrations.
These initial registrational trials did not compare boosted 
ATV with other PIs or non-nucleoside reverse transcriptase 
inhibitors (NNRTI), and boosted ATV was initially 
disregarded for use in drug-naïve patients, at least in North 
America. These trials were followed by the AI424-089 
study, a randomized, multicenter, 96-week study designed 
to compare the efﬁ  cacy and safety of ATV/r to ATV, each 
given once daily in combination with once-daily lamivudine 
and extended-release stavudine in drug-naïve patients.51 In 
this comparison of boosted and unboosted ATV, the overall 
efﬁ  cacy results were comparable. However, while not sta-
tistically signiﬁ  cant, the rates of response were higher and 
emergence of PI resistance lower in subjects on ATV/r than 
in those on unboosted ATV. Based on these results, other 
studies using boosted ATV in treatment-naïve subjects were 
designed. The concern about a lower potency of unboosted 
ATV has been recorded in several antiretroviral treatment 
guidelines, in which ATV alone is only described as an 
alternative (but not preferred) PI in drug-naïve patients.24 
Unboosted ATV may be chosen in highly selected circum-
stances as initial therapy for patients when a once-daily 
regimen without r is desired, in subjects not candidates for 
NNRTI-based regimens, and in patients with underlying 
cardiovascular risk factors in whom hyperlipidemia may be 
particularly undesirable.52 Of course, TDM would be desir-
able in these circumstances.
A recent prospective randomized phase IV study has 
explored the efﬁ  cacy of the combination of unboosted ATV 
plus enteric-coated didanosine (ddI) and emtricitabine (FTC) 
in comparison with efavirenz and ZDV/3TC or TDF/FTC in 
1045 patients, mainly from resource-limited countries (ACTG 
A5175). The rationale for the use of a ddI/FTC/ATV regimen is 
obvious, since this once-daily combination might be relatively 
inexpensive, not require refrigeration of any compound (one of 
the main drawbacks when r has to be used), and be relatively 
cheaper. Unfortunately, after a planned interim review, the 
study found a signiﬁ  cantly greater risk of treatment failure with 
ddI + FTC + ATV compared with ZDV + 3TC + EFV.53
Finally, ATV/r has been compared with two of the 
preferred boosted PI regimens in treatment-naïve patients: 
fosamprenavir (FPV)/r and LPV/r. The ALERT study was 
a relatively small randomized study comparing FPV/r ver-
sus ATV/r both long with TDF/FTC.54 The study included 
106 participants, 53 in each arm. It should be noted that 
FPV (1400 mg) was used once a day with only 100 mg of 
r instead of the usual twice-daily regimen using 200 mg 
of r. Both regimens performed similarly well with respect 
to virologic suppression and CD4 count gains. At week 48, 
intent-to-treat analysis showed similar responses to FPV/r 
and ATV/r, being plasma HIV-RNA  50 copies/mL in 75% 
(40/53) and 83% (44/53) of patients, respectively. Fasting 
total LDL/HDL cholesterol changes from baseline were also 
similar, although week 48 median fasting triglycerides were 
higher with FPV/r than with ATV/r (150 versus 131 mg/dL, 
respectively). FPV/r-treated patients experienced fewer Therapeutics and Clinical Risk Management 2009:5 109
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treatment-associated grade 2–4 adverse events (15% versus 
57%), with differences mainly driven by ATV-associated 
hyperbilirubinemia.
The most relevant trial using ATV/r in treatment-
naïve patients conducted so far is the CASTLE study.55 
In this open-label, international, non-inferiority study, 883 
antiretroviral-naïve patients were randomly assigned to receive 
ATV/r 300/100 mg qd or LPV/r 400/100 mg twice daily, in 
combination with a ﬁ  xed-dose of TDF/FTC. At 48 weeks, 
plasma HIV-RNA  50 copies/mL were seen at similar rates 
in both arms (78% and 76%, respectively) and CD4 gains 
were also comparable. Serious adverse events occurred in 
12% of patients in the ATV/r group and in 10% of patients in 
the LPV/r group. However, a better lipid proﬁ  le was observed 
in patients taking ATV/r compared to those taking LPV/r. 
Moreover, gastrointestinal side effects were more common 
in the LPV/r group, while those receiving ATV/r were more 
likely to experience jaundice. Both treatments, however, were 
very well tolerated overall. It should be noted that CASTLE 
was an open-label study and 3 capsules twice daily of LPV/r 
instead of the current 2 tablets bid were used.
Altogether, these studies support the use of once-daily 
ATV/r as a good ﬁ  rst-line treatment option in drug-naïve 
patients. Studies comparing the effectiveness of ATV/r 
and efavirenz (ACTG A5202) or nevirapine (ARTEN and 
NEwArT studies) as ﬁ  rst-line therapy are ongoing.
Atazanavir in treatment-experienced 
failing patients
It must be acknowledged that the approval of ATV was accel-
erated based on the results of another three clinical trials run in 
patients with virological failure under PI-containing regimens 
(Table 5). In this adverse setting, the AI424-009 study56 com-
pared two rescue regimens based on ATV (400 and 600 mg) 
plus SQV (1200 mg) once a day versus SQV/r (400/400 mg) 
twice daily either in combination with two NRTI chosen based 
on phenotypic susceptibility data. The rationale for using 
ATV + SQV was based on the evidence of a booster effect of 
the former on SQV by inhibiting the cytochrome P450 3A4 
isoenzyme in the liver.57 More than 85% of patients had prior 
PI experience and the median duration of prior PI therapy 
was approximately 2 years. The best virological response 
at 48 weeks was found in the ATV 400 mg qd group (41%) 
over the ATV 600 mg qd (29%) or SQV/r groups (35%). 
There were fewer adverse event discontinuations in the 
ATV/r groups (9% and 11%, respectively) than in the SQV/r 
arm (30%). Moreover, none of the ATV groups showed the 
adverse effects on lipids seen in the SQV/r arm.
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Despite the good performance of boosted ATV-based 
regimens in short- and long-term treatment of antiretroviral-
experienced patients, its efﬁ  cacy may be impaired in heav-
ily pretreated patients. In terms of virological potency, 
many studies have concluded that as salvage therapy in 
antiretroviral-experienced patients, ATV/r could be a 
valuable option, unless a high number of PI resistance 
mutations are present.60,61 Moving a further step, the results 
of the French prospective NADIS cohort have concluded 
that ATV/r-containing regimens may be useful in heavily 
antiretroviral-experienced patients as long as failure has not 
occurred on LPV/r.11
Studies comparing the antiretroviral efﬁ  cacy, safety 
and effect of serum lipids of ATV/r versus LPV/r in HIV 
subjects who have experienced their ﬁ  rst virologic failure 
while receiving a NNRTI-containing HAART regimen are 
currently ongoing (eg, AI424-103 trial).
Finally, boosted double PI regimens (r plus 2 additional 
PIs) gained interest a few years ago as a treatment option 
for multiple treatment-experienced patients with little or 
no options. The advent of new antiretrovirals, such as enfu-
virtide, raltegravir, darunavir, maraviroc and etravirine, 
with the ability to achieve long-term viral load reductions 
in heavily antiretroviral-experienced patients with relatively 
few, manageable toxicities, and low drug interactions has 
clearly halted the research on double boosted PIs.
Atazanavir in switch studies
The long-term adverse effects and the difﬁ  culty of continuous 
almost perfect adherence to antiretroviral regimens have led 
to assessment of the impact of strategies aimed to simplify 
therapy. Obviously, a requirement is preservation of viral 
suppression and reduced risk of toxicities. As a simpliﬁ  cation 
strategy, ATV-based regimens may offer several therapeutic 
advantages, including a convenient once-daily dosing sched-
ule, low pill burden and lack of metabolic undesirable side 
effects compared to efavirenz or other PI-based regimens 
(Table 6).
In the AI424-044 study,62 patients completing  48 weeks 
in another trial (AI424-008) with a plasma HIV-RNA  10,000 
copies/mL were randomized to continue on ATV (400 or 
600 mg qd) or switch from nelﬁ  navir to ATV (400 mg qd). 
After 24 weeks of ATV therapy, 83%, 85% and 87% of sub-
jects in the ATV 400 mg, ATV 600 mg and switch groups, 
respectively, had plasma HIV-RNA  400 copies/mL. These 
ﬁ  gures were 76%, 76% and 63%, respectively, at week 48 in 
the prior AI424-008 study. Patients switched from nelﬁ  navir 
to ATV showed signiﬁ  cant mean declines in total cholesterol 
In the AI424-043 study58 all patients had failed with at 
least one PI and were rescued with unboosted ATV versus 
LPV/r along with a nucleoside backbone selected according 
to resistance testing. LPV/RTV resulted in a signiﬁ  cantly 
greater reduction in plasma HIV-RNA than unboosted ATV 
(−2.02 versus −1.59 log10 copies/mL, p   0.001) at week 48. 
Moreover, CD4 gains were higher with LPV/r than with ATV 
(169 versus 112 cells/μL). However, in the subset of patients 
with lack of NRTI resistance mutations at baseline, both 
regimens demonstrated comparable virologic suppression. 
The metabolic indulgence of ATV was especially manifest 
in this study. While LPV/r increased lipid levels and induced 
insulin resistance, these parameters remained stable in the 
ATV arm.
The third study (AI424-045) compared boosted ATV 
with LPV/r.59 The trial expected to ﬁ  nd comparable efﬁ  -
cacy and less toxicity with ATV/r. Patients who had failed 
two or more HAART regimens were randomized to ATV/r 
(300/100 mg qd), ATV/SQV (400/1200 mg qd) or LPV/r 
(400/100 mg bid), all along with TDF once daily and another 
NRTI. Approximately 40% of patients harbored  4 NRTI 
resistance mutations and more than one third harbored  4 
PI resistance mutations. The virologic and immunologic 
results were worse for patients treated with ATV/SQV as 
compared with the other two groups (LPV/r and ATV/r), 
and therefore this arm was stopped at 24 weeks. In the 
intention-to-treat analysis at 96 weeks, similar virological 
efﬁ  cacy was demonstrated for the remaining ATV/r and 
LPV/r arms, with 44% versus 46% of patients achieving 
 400 HIV-RNA copies/mL, respectively. CD4 gains at that 
time were also comparable (+160 and +142 cells/μL, respec-
tively).33 Although response rates were similar when fewer 
than 4 PI-resistance associated mutations were present at 
baseline, LPV/r was superior to ATV/r in patients with more 
PI resistance mutations. This result suggested that ATV/r 
is of similar efﬁ  cacy to LPV/r in antiretroviral-experienced 
patients with a limited extent of PI resistance, but it was 
inferior when a greater PI resistance was present. The tol-
erability of the three regimens was good and comparable, 
although only the ATV-containing groups beneﬁ  ted from less 
frequent gastrointestinal disturbances and signiﬁ  cant reduc-
tions in total cholesterol, LDL cholesterol, and triglyceride 
concentrations. Moreover, in contrast with LPV/r, patients 
on ATV/r showed a signiﬁ  cantly lower use of anti-diarrheal 
and lipid-lowering agents. The only drawback was grade 3–4 
hyperbilirubinemia, which developed in 53% on ATV/r, a 
rate greater than expected and for which there is no clear 
explanation so far.Therapeutics and Clinical Risk Management 2009:5 111
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(−16%), fasting LDL cholesterol (−21%), and fasting triglyc-
erides (−28%) (p   0.0001) by week 12 of ATV therapy, 
approaching baseline values.
Further studies have conﬁ  rmed the benign lipid proﬁ  le 
of ATV. The AI424-067 study63 was designed as a switch 
trial with the aim of managing hyperlipidemia in patients 
with well-controlled HIV replication. Preliminary 12-week 
data were reported a few years ago from 246 participants 
on stable HAART with undetectable viral load and elevated 
LDL cholesterol. They were randomly assigned to either con-
tinue their current PI-based regimen or switch to unboosted 
ATV while remaining on the same NRTIs. After 12 weeks, 
patients in the ATV arm maintained virological suppression 
while experiencing a 35% decrease in triglycerides, a 15% 
reduction in LDL cholesterol, an 18% drop in total cholesterol, 
and 14% increase in HDL cholesterol. In addition, the study 
comprised an immediate switch group in which the PI was 
replaced by ATV 400 mg qd and a delayed switch group in 
which subjects continued to receive their prior PI-containing 
regimen for the ﬁ  rst 24 weeks and then switched to ATV 
400 mg qd. The results at 48 weeks conﬁ  rmed that the switch 
from any PI (r-boosted or not) to ATV 400 mg qd resulted 
in clinically relevant reductions in fasting LDL cholesterol. 
However, rates of viral rebound were 15% and 10% in the 
immediate and delayed switch groups, respectively. It should 
be noted that most of these patients had been exposed to 
suboptimal dual NRTI therapy in the past, and in this situation 
boosted instead of unboosted ATV would have been preferred 
by most clinicians to ensure enough drug exposure.64
The Switch to Another Protease Inhibitor Study (SWAN 
or AI424-097 study)65 was a 48-week, open-label, prospective 
trial involving HIV patients with virologic suppression who 
were receiving stable PI-based regimens (with or without r). 
Patients were randomized 2:1 to switch to ATV (400 mg/day) 
or, if they were receiving TDF, to ATV/r (300/100 mg qd) 
or to continue on their prior PI. After 48 weeks, patients 
who switched to ATV showed signiﬁ  cantly fewer total 
cholesterol, fasting triglyceride, and non-HDL cholesterol 
Table 6 Main switch studies with atazanavir
Study Phase n Backbone Previous 
regimen
Intervention Follow-up
(weeks)
Main conclusion
AI424-04462 III 346 d4T + 3TC ATV 400 mg qd Continue on ATV (400 or 
600 mg) or switch from 
NFV to ATV 400 mg qd
24 Maintenance of virologic suppression 
and signiﬁ  cant improvement in lipid 
proﬁ  le in patients switched to ATV
ATV 600 mg qd
NFV 1250 mg bid
AI424-06768 III 246 2 NRTI PI with or 
without RTV
Immediate switch to ATV 
400 mg qd or delayed 
switch after 24 weeks
48 Virologic rebounds  50 copies/mL, 
15% in immediate switch and 10% in 
delayed switch group. Improvement 
in lipid proﬁ  le in hyperlipidemic 
patients
AI424-09765 III 419 2 NRTI PI with or 
without RTV
Continue existing PI or 
switch to ATV (400 mg qd) or 
to ATV/RTV (300/100 mg qd) 
if receiving TDF
48 Maintenance of virologic suppression 
and improvement in lipid proﬁ  le in 
patients switched to ATV
SLOAT66 IV 189 2 NRTI LPV/RTV Continue on LPV/RTV or 
switch to ATV (400 mg qd) or 
to ATV/RTV (300/100 mg qd) 
if receiving TDF
24 Maintenance of virologic suppression 
and improvement in lipid proﬁ  le in 
patients switched to ATV
ATAZIP67 IV 265 2 NRTI LPV/RTV Continue on LPV/RTV or 
switch to ATV ATV/RTV 
(300/100 mg qd)
48 Maintenance of virologic suppression 
and improvement in lipid proﬁ  le in 
patients switched to ATV
ReAL73 IV 200 2 NRTI PI/ritonavir
(72% LPV/RTV)
Continue existing PI or 
switch to ATV/RTV 
(300/100 mg qd) in 
patients with 
lipohypertrophy
48 Maintenance of virologic suppression 
and improvement in lipid proﬁ  le but 
no signiﬁ  cant change in body compo-
sition in patients switched to ATV
Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; ITT, intent-to-treat;   VL, viral load; 3TC, lamivudine; d4T, stavudine; LPV, lopinavir; NFV, 
nelﬁ  navir; RTV, ritonavir; ATV, atazanavir; bid, twice daily; qd, once daily.Therapeutics and Clinical Risk Management 2009:5 112
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elevations than did patients in the comparator PI group 
(p   0.001). For patients with prior exposure to boosted PI 
regimens, the 2 treatment groups had comparable rates of 
virologic rebound (8% for the ATV group versus 11% for 
the comparator PI group). In contrast, signiﬁ  cantly lower 
rebound rates were recognized for ATV versus comparator 
PI groups in the subset of patients with prior exposure to 
unboosted PIs (5% versus 22%; p   0.001). A limitation 
of the study was that nearly half of the study participants 
entered the trial taking an obsolete unboosted PI modality 
and almost everyone switched to ATV did not take r, which 
is not the current standard of care.
The AI424-100 study tried to compare the change from 
baseline in fasting non-HDL cholesterol between hyperlipid-
emic subjects who were switched to an ATV/RTV-regimen 
and those who continued on a LPV/r regimen. Unfortu-
nately, the study was prematurely discontinued due to poor 
enrolment and no efﬁ  cacy analyses were performed. This 
issue was ﬁ  nally addressed by two Spanish phase IV studies, 
the SLOAT and the ATAZIP trials.
In the Simpliﬁ  cation Lopinavir to Atazanavir (SLOAT) 
study,66 patients receiving LPV/r-based regimens (with or 
without hyperlipidemia) and having undetectable plasma 
HIV-RNA for longer than 24 weeks were randomized to 
continue on the same therapy or switch to ATV (400 mg qd) 
or to ATV/r (300/100 mg qd) if receiving TDF. The rate of 
virological failures at 48 weeks did not differ between groups. 
A signiﬁ  cant reduction (p   0.001) was seen in median total 
cholesterol (−19 mg/dL) and triglycerides (−80 mg/dL) in the 
ATV switch group, whereas no signiﬁ  cant changes occurred 
in the control LPV/r arm. Greater reductions in total choles-
terol and triglycerides were seen in patients switched to ATV 
without r boosting.
The ATAZIP study67 evaluated 248 individuals on stable 
LPV/RTV-based therapy (plasma HIV-RNA  200 copies/mL 
for longer than 6 months) who were randomized to either 
continue on the capsule formulation of LPV/r twice daily 
or switch to ATV/r (300/100 mg) qd. All individuals with 
more than 4 PI-associated resistance mutations and/or who 
had failed more than 2 PI-containing regimens were excluded 
from the study. Although HDL cholesterol did not change 
in either group, signiﬁ  cantly more favorable shifts in total 
cholesterol, LDL cholesterol and triglycerides were observed 
in the ATV/r arm in comparison to the LPV/r arm. Virologic 
failure was uncommon and occurred in only 5% of ATV/r 
recipients and 6% of LPV/r patients. Virologic failure was 
typically associated with a prior history of PI failure and/or 
presence of baseline major PI resistance mutations.
In addition to a better lipid proﬁ  le, several studies have 
attempted to evaluate the effects on glucose tolerance following 
switch to ATV from PI-based regimens. The rationale was 
derived from prior information showing that ATV seems to 
have less effect on glucose metabolism than other PIs.68 In a 
study which included 21 highly pretreated HIV-infected sub-
jects with metabolic alterations, the switch to an unboosted 
ATV-containing regimen revealed a signiﬁ  cant improvement in 
glucose tolerance.69 Likewise, in 9 HIV-infected men with dys-
lipidemia under a stable PI-containing regimen, the switch to 
ATV/RTV improved signiﬁ  cantly insulin resistance, measured 
by the gold-standard euglycemic clamp method.70
ATV is less likely to induce lipodystrophy than other PIs. 
Based on data at week 48 from a substudy of the AI424-034 
trial,5 it would appear that ATV has little effect on changes 
in fat redistribution.71 This substudy focused on subjects 
with CD4 counts  100 cells/μL, whose initial antiretroviral 
therapy consisted of ZDV + 3TC plus either EFV or ATV. 
There was no evidence of lipoatrophy at 48 weeks in any 
treatment arm; although there was a small increase in both 
abdominal subcutaneous and limb fat levels, which was not 
statistically signiﬁ  cant. Moreover, there was an increase in the 
visceral fat by computed tomography with either drug com-
bination. This study could be criticized in that the 48-week 
follow-up might be insufﬁ  cient to detect subtle or delayed 
deleterious effects. However, in the AI424-007 trial, lipodys-
trophy continued to be infrequent and not signiﬁ  cant com-
pared to nelﬁ  navir after 48 weeks on unboosted ATV.43
It is still unclear whether a switch from other PIs to ATV 
could ameliorate or even improve lipodystrophic effects 
of prior antiretroviral regimens. In a case series, 3 patients 
experienced a regression of dorso-cervical and abdominal 
fat accumulation after switching the existing PI to ATV.72 
However, switching from PIs to ATV/r did not signiﬁ  cantly 
reduce visceral fat accumulation in the abdomen at 48 weeks 
in the ReAL study.73 This trial evaluated the impact on body 
composition of switching from any twice-daily r-boosted PI 
to a once-daily ATV/r regimen in patients with lipohyper-
trophy (fat accumulation). Participants had been taking a 
boosted PI for a median of 24 months (LPV/r in 72%). No 
signiﬁ  cant differences in visceral fat were seen comparing 
the two groups after 1 year, suggesting no meaningful effect 
of treatment switch on the primary study outcome. However, 
patients who switched to ATV experienced a signiﬁ  cant 
reduction in all fasting lipids, while antiviral efﬁ  cacy was 
preserved. This study is still ongoing and results at week 96 
will soon be available. Nevertheless, lipid improvements seen 
with ATV most likely will not translate into signiﬁ  cant body Therapeutics and Clinical Risk Management 2009:5 113
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fat changes within 2 years, since fat abnormalities generally 
take longer to recover. Long-term studies will be needed to 
assess the true effect of ATV on lipodystrophy.
Although ATV has proved to be a more metabolic-friendly 
drug that other antiretrovirals, and may help to manage 
metabolic side effects, it remains unclear weather switching 
to ATV may be a better approach than adding lipid-lowering 
medications to prior medications. However, any improvement 
in the lipid proﬁ  le on ATV is likely to be beneﬁ  cial in terms of 
reducing cardiovascular risk, and may decrease the required 
dose of lipid-lowering medications. A recent retrospective 
study has shown that a switch to ATV in HIV-infected anti-
retroviral-experienced patients caused signiﬁ  cant reductions 
in plasma lipids and a modest but signiﬁ  cant reduction in 
the normalized-for-age cardiovascular risk score, mainly in 
patients with higher baseline total cholesterol and triglycer-
ides.74 Nevertheless, another study revealed that the switch 
from PIs to ATV in antiretroviral-experienced patients did not 
result in recognizable improvements in endothelial function 
despite beneﬁ  ts in the serum lipids.75
Atazanavir/ritonavir monotherapy
In an attempt to simplify antiretroviral regimens as much as 
possible, recent reports have claimed that PI/r monotherapy 
could be an alternative option in some patients, especially 
as a maintenance strategy once virological control has been 
achieved. The proof-of concept studies for this strategy 
were originally conducted with LPV/r,76,77 following which 
3 uncontrolled studies with ATV/RTV monotherapy have 
been performed, resulting in conﬂ  icting results.
ATV/r was tested in a prospective pilot study of 34 HIV 
adults with virological suppression for  48 weeks receiv-
ing their ﬁ  rst PI regimen.78 All participants switched to 
ATV/r at entry and discontinued the NRTI backbone after 
6 weeks. Three participants (9%) experienced virologic 
failure at weeks 12, 14 and 20 after simpliﬁ  cation, with 
plasma HIV-RNA levels of 4730, 1285 and 28397 copies/mL, 
respectively. Intriguingly, resistance testing at failure did 
not identify any PI resistance mutation. Plasma ATV con-
centrations at failure were low or below detection in 2 out of 
3 subjects. The authors concluded that ATV/r maintenance 
monotherapy could be a valuable option in a subset of HIV 
patients. However, predicting those who would fail was 
unclear.
In another pilot trial using ATV/r as maintenance therapy, 
premature discontinuation was recommended when 15 of 
the planned 30 patients had been recruited, because 5 cases 
of virological failure were documented. In failing patients, 
viral rebound occurred between weeks 12 and 16. Plasma 
ATV concentrations did not predict the outcome. Again, 
no PI resistance mutations were found in failing patients.79 
The investigators concluded that ATV/r as maintenance 
monotherapy in HIV-1 infection should not be considered 
as potent as conventional triple antiretroviral therapy.
The third study, named ATARITMO, tried to determine 
the feasibility of ATV/r maintenance monotherapy along with 
its effects on viral replication in compartments other than 
plasma, such as the CSF and seminal plasma. At week 24, 3/20 
patients had detectable viremia (HIV-RNA  100 copies/mL) 
in CSF and 2/15 in semen, despite viral suppression in plasma 
( 50 HIV-RNA copies/mL). Interestingly, samples with 
elevated HIV-RNA ( 500 copies/mL) in CSF were all wild 
type in CSF.80 Altogether, the general view is that ATV/r 
monotherapy, as with other PIs, must not be considered as 
an acceptable optional strategy when any modality of triple 
antiretroviral regimens can be afforded.81
Conclusion
ATV has opened a new PI era with safer and more conve-
nient compounds. While it retains the potency of the oldest 
robust PIs, it offers the advantage of simplicity and minimal 
toxicity both in treatment-naïve and in treatment-experienced 
patients. Once the possibility of controlling HIV infection 
has already been achieved by choosing combinations of 
the 25 drugs currently available within the HIV treatment 
armamentarium, the availability of this kind of friendly drug 
may enable an improvement in the quality of life, a variable 
of growing relevance as the life expectancy of HIV-infected 
persons is approaching that of uninfected individuals.
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